The CRP–albumin–lymphocyte index provides enhanced prognostic value in liver cancer compared to the TNM staging system

Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP–albumin–lymphocyte (CALLY) index—a composite indicator of systemic inflammation, nutritional status, and immune function—as a prognostic tool for live...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 15; no. 1; pp. 20090 - 11
Main Authors Zhao, Hong, Yin, Bing, Li, Xiang-Rui, Liu, Xiao-Yue, Bu, Zhao-Ting, Shi, Han-Ping
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 19.06.2025
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP–albumin–lymphocyte (CALLY) index—a composite indicator of systemic inflammation, nutritional status, and immune function—as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan–Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model’s performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39–0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572–0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes.
AbstractList Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP–albumin–lymphocyte (CALLY) index—a composite indicator of systemic inflammation, nutritional status, and immune function—as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan–Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model’s performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39–0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572–0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes.
Abstract Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP–albumin–lymphocyte (CALLY) index—a composite indicator of systemic inflammation, nutritional status, and immune function—as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan–Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model’s performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39–0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572–0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes.
Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP-albumin-lymphocyte (CALLY) index-a composite indicator of systemic inflammation, nutritional status, and immune function-as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan-Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model's performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39-0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572-0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes.Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP-albumin-lymphocyte (CALLY) index-a composite indicator of systemic inflammation, nutritional status, and immune function-as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan-Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model's performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39-0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572-0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes.
Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP–albumin–lymphocyte (CALLY) index—a composite indicator of systemic inflammation, nutritional status, and immune function—as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan–Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model’s performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39–0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572–0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes.
ArticleNumber 20090
Author Yin, Bing
Li, Xiang-Rui
Liu, Xiao-Yue
Shi, Han-Ping
Bu, Zhao-Ting
Zhao, Hong
Author_xml – sequence: 1
  givenname: Hong
  surname: Zhao
  fullname: Zhao, Hong
  organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University
– sequence: 2
  givenname: Bing
  surname: Yin
  fullname: Yin, Bing
  organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University
– sequence: 3
  givenname: Xiang-Rui
  surname: Li
  fullname: Li, Xiang-Rui
  organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University
– sequence: 4
  givenname: Xiao-Yue
  surname: Liu
  fullname: Liu, Xiao-Yue
  organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University
– sequence: 5
  givenname: Zhao-Ting
  surname: Bu
  fullname: Bu, Zhao-Ting
  organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University
– sequence: 6
  givenname: Han-Ping
  surname: Shi
  fullname: Shi, Han-Ping
  email: shihp@ccmu.edu.cn
  organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40537551$$D View this record in MEDLINE/PubMed
BookMark eNp9ks2O0zAQxyO0iF2WfQEOKBIXLgF_TWIfUbXASsuHUO-Wa0_SVIld7KSinHgH3pAnwW2XBXHAlxmNfjPjv_1_XJz54LEonlLykhIuXyVBQcmKMKgIVxKq5kFxwYiAinHGzv7Kz4urlDYkH2BKUPWoOBcEeANAL4pvyzWWi8-ffn7_YYbVPPY-Z8N-3K6D3U9Y9t7h13Ibw653mEr0a-MtukOl8yFNvS13ZpgPYDn0O4ylPQA5hHFrYianUE55x_LD-zJNput9V6Z9mnB8UjxszZDw6i5eFss318vFu-r249ubxevbygoup6qVHFpiiALHsRWtcUgaI4SUitq6Nc2KWmyIQ2CSNYZIAIWSSueUddbwy-LmNNYFs9Hb2I8m7nUwvT4WQuy0iVnHgHolpQULXNIaBCGtAmhrySi0K2Gks3nWi9OsLP_LjGnSY58sDoPxGOak82uzmivS8Iw-_wfdhDn6LPRICVmDgkw9u6Pm1Yju_nq_PygD7ATYGFKK2N4jlOiDEfTJCDobQR-NoJvcxE9NKcO-w_hn93-6fgEeQ7c1
Cites_doi 10.3389/fimmu.2023.1131496
10.1016/j.ccell.2023.02.016
10.3350/cmh.2022.0316
10.1007/s00520-023-07997-9
10.3389/fmed.2025.1543665
10.1007/s12072-015-9665-6
10.1111/liv.15115
10.1016/j.nut.2023.112191
10.1016/j.jhep.2018.12.001
10.1007/s00595-016-1433-2
10.1016/j.jhep.2022.08.021
10.1016/j.hpb.2021.06.414
10.1038/s41568-021-00383-9
10.1038/s41576-022-00553-x
10.1016/j.jhep.2022.06.012
10.1016/j.intimp.2021.108220
10.3389/fonc.2020.00171
10.21873/anticanres.16572
10.1007/s11695-021-05237-9
10.1016/j.bbcan.2019.188314
10.1016/j.suronc.2023.101911
10.17998/jlc.20.2.106
10.3390/cancers13195018
10.3389/fimmu.2022.1002652
10.1186/s12943-019-1047-6
10.1038/nrdp.2016.18
10.1007/s12029-023-01008-0
10.1016/j.hpb.2023.08.012
10.1056/NEJMra1713263
10.1186/s13046-023-02609-0
10.1055/s-0038-1676806
10.1016/j.jhep.2022.02.032
10.1111/acel.13512
10.1002/ags3.12637
10.1038/s41571-023-00734-5
10.1021/jacs.3c05052
10.1038/nature16969
ContentType Journal Article
Copyright The Author(s) 2025
2025. The Author(s).
Copyright Nature Publishing Group 2025
Copyright_xml – notice: The Author(s) 2025
– notice: 2025. The Author(s).
– notice: Copyright Nature Publishing Group 2025
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
DOA
DOI 10.1038/s41598-025-03985-7
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Proquest Medical Database
Science Database
Biological Science Database (Proquest)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central - New (Subscription)
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 11
ExternalDocumentID oai_doaj_org_article_b88c5c538165400f955f68215fb4a8dc
40537551
10_1038_s41598_025_03985_7
Genre Journal Article
Comparative Study
GroupedDBID 0R~
4.4
53G
5VS
7X7
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
AASML
ABDBF
ABUWG
ACGFS
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AFPKN
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M1P
M2P
M7P
M~E
NAO
OK1
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
3V.
7XB
88A
8FK
K9.
M48
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
ID FETCH-LOGICAL-c438t-f835f0a095d3ef4fade07a448891c6fa7b1ce70de52827a08559e818dd9cdca3
IEDL.DBID C6C
ISSN 2045-2322
IngestDate Wed Aug 27 01:29:07 EDT 2025
Fri Jul 11 17:03:44 EDT 2025
Sat Aug 23 14:09:59 EDT 2025
Mon Jul 21 06:06:24 EDT 2025
Thu Jul 03 08:44:05 EDT 2025
Fri Jun 20 01:11:51 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Liver cancer
The CALLY index
Survival
Nomogram
Language English
License 2025. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c438t-f835f0a095d3ef4fade07a448891c6fa7b1ce70de52827a08559e818dd9cdca3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.nature.com/articles/s41598-025-03985-7
PMID 40537551
PQID 3222486595
PQPubID 2041939
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_b88c5c538165400f955f68215fb4a8dc
proquest_miscellaneous_3222639073
proquest_journals_3222486595
pubmed_primary_40537551
crossref_primary_10_1038_s41598_025_03985_7
springer_journals_10_1038_s41598_025_03985_7
PublicationCentury 2000
PublicationDate 2025-06-19
PublicationDateYYYYMMDD 2025-06-19
PublicationDate_xml – month: 06
  year: 2025
  text: 2025-06-19
  day: 19
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2025
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Z Liu (3985_CR3) 2019; 70
3985_CR36
BS Kim (3985_CR30) 2020; 20
H Rumgay (3985_CR4) 2022; 77
Q Wang (3985_CR32) 2023; 2
H Xu (3985_CR34) 2022; 1
XY Liu (3985_CR14) 2023; 31
K Furukawa (3985_CR12) 2023; 47
X Li (3985_CR8) 2021; 21
M Zhou (3985_CR33) 2023; 2
T Aoyama (3985_CR19) 2023; 43
S Mohammed (3985_CR44) 2021; 20
C Lu (3985_CR26) 2019; 18
P Dasgupta (3985_CR6) 2020; 10
H Zhang (3985_CR15) 2023; 116
3985_CR18
M Peiseler (3985_CR43) 2022; 77
JM Argilés (3985_CR23) 2023; 20
JM Llovet (3985_CR1) 2016; 2
WT Dou (3985_CR11) 2023; 145
SQ Lang (3985_CR17) 2025; 12
S Choi (3985_CR5) 2023; 29
A Villanueva (3985_CR2) 2019; 380
K Yoshimatsu (3985_CR24) 2017; 44
D Anwanwan (3985_CR7) 2020; 1873
BI Carr (3985_CR10) 2021; 18
Z Seferbekova (3985_CR22) 2023; 24
R Spinella (3985_CR39) 2016; 10
YY Wang (3985_CR35) 2003; 66
J Cui (3985_CR31) 2023; 2
M Tsunematsu (3985_CR20) 2023; 7
KE de Visser (3985_CR21) 2023; 41
MB Schoenberg (3985_CR27) 2021; 101
X Fu (3985_CR40) 2022; 42
YM Yang (3985_CR42) 2019; 39
M Barsch (3985_CR25) 2022; 77
YP Mendoza (3985_CR38) 2021; 31
BI Carr (3985_CR9) 2018; 15
C Dix (3985_CR45) 2022; 13
Y Iseki (3985_CR29) 2017; 47
Y Liu (3985_CR41) 2023; 42
S Omiya (3985_CR37) 2023; 25
M Yang (3985_CR13) 2023; 14
H Iida (3985_CR16) 2022; 24
C Ma (3985_CR28) 2016; 531
References_xml – volume: 14
  start-page: 1131496
  year: 2023
  ident: 3985_CR13
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2023.1131496
– volume: 2
  issue: 1
  year: 2023
  ident: 3985_CR33
  publication-title: Precis. Nutr.
– volume: 41
  start-page: 374
  issue: 3
  year: 2023
  ident: 3985_CR21
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2023.02.016
– volume: 29
  start-page: 433
  issue: 2
  year: 2023
  ident: 3985_CR5
  publication-title: Clin. Mol. Hepatol.
  doi: 10.3350/cmh.2022.0316
– volume: 31
  start-page: 533
  issue: 9
  year: 2023
  ident: 3985_CR14
  publication-title: Support Care Cancer.
  doi: 10.1007/s00520-023-07997-9
– volume: 12
  start-page: 1543665
  year: 2025
  ident: 3985_CR17
  publication-title: Front. Med. (Lausanne).
  doi: 10.3389/fmed.2025.1543665
– volume: 10
  start-page: 124
  issue: 1
  year: 2016
  ident: 3985_CR39
  publication-title: Hepatol. Int.
  doi: 10.1007/s12072-015-9665-6
– volume: 2
  issue: 1
  year: 2023
  ident: 3985_CR32
  publication-title: Precis. Nutr.
– volume: 42
  start-page: 696
  issue: 3
  year: 2022
  ident: 3985_CR40
  publication-title: Liver Int.
  doi: 10.1111/liv.15115
– volume: 116
  year: 2023
  ident: 3985_CR15
  publication-title: Nutrition
  doi: 10.1016/j.nut.2023.112191
– volume: 70
  start-page: 674
  issue: 4
  year: 2019
  ident: 3985_CR3
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2018.12.001
– volume: 47
  start-page: 743
  issue: 6
  year: 2017
  ident: 3985_CR29
  publication-title: Surg. Today.
  doi: 10.1007/s00595-016-1433-2
– volume: 77
  start-page: 1598
  issue: 6
  year: 2022
  ident: 3985_CR4
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2022.08.021
– volume: 66
  start-page: 593
  issue: 10
  year: 2003
  ident: 3985_CR35
  publication-title: J. Chin. Med. Assoc.
– volume: 18
  start-page: 1626
  issue: 2
  year: 2021
  ident: 3985_CR10
  publication-title: Clin. Pract. (Lond).
– volume: 24
  start-page: 101
  issue: 1
  year: 2022
  ident: 3985_CR16
  publication-title: HPB (Oxford).
  doi: 10.1016/j.hpb.2021.06.414
– volume: 21
  start-page: 541
  issue: 9
  year: 2021
  ident: 3985_CR8
  publication-title: Nat. Rev. Cancer.
  doi: 10.1038/s41568-021-00383-9
– volume: 24
  start-page: 295
  issue: 5
  year: 2023
  ident: 3985_CR22
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/s41576-022-00553-x
– volume: 77
  start-page: 1136
  issue: 4
  year: 2022
  ident: 3985_CR43
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2022.06.012
– volume: 101
  issue: Pt A
  year: 2021
  ident: 3985_CR27
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2021.108220
– volume: 10
  start-page: 171
  year: 2020
  ident: 3985_CR6
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.00171
– volume: 43
  start-page: 3849
  issue: 9
  year: 2023
  ident: 3985_CR19
  publication-title: Anticancer Res.
  doi: 10.21873/anticanres.16572
– volume: 31
  start-page: 2817
  issue: 6
  year: 2021
  ident: 3985_CR38
  publication-title: Obes. Surg.
  doi: 10.1007/s11695-021-05237-9
– volume: 44
  start-page: 906
  issue: 10
  year: 2017
  ident: 3985_CR24
  publication-title: Gan To Kagaku Ryoho
– volume: 1873
  issue: 1
  year: 2020
  ident: 3985_CR7
  publication-title: Biochim. Biophys. Acta Rev. Cancer.
  doi: 10.1016/j.bbcan.2019.188314
– volume: 47
  year: 2023
  ident: 3985_CR12
  publication-title: Surg. Oncol.
  doi: 10.1016/j.suronc.2023.101911
– volume: 20
  start-page: 106
  issue: 2
  year: 2020
  ident: 3985_CR30
  publication-title: J. Liver Cancer.
  doi: 10.17998/jlc.20.2.106
– ident: 3985_CR18
  doi: 10.3390/cancers13195018
– volume: 13
  start-page: 1002652
  year: 2022
  ident: 3985_CR45
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.1002652
– volume: 1
  issue: 2
  year: 2022
  ident: 3985_CR34
  publication-title: Precis. Nutr.
– volume: 18
  start-page: 130
  issue: 1
  year: 2019
  ident: 3985_CR26
  publication-title: Mol. Cancer.
  doi: 10.1186/s12943-019-1047-6
– volume: 2
  start-page: 16018
  year: 2016
  ident: 3985_CR1
  publication-title: Nat. Rev. Dis. Primers.
  doi: 10.1038/nrdp.2016.18
– ident: 3985_CR36
  doi: 10.1007/s12029-023-01008-0
– volume: 25
  start-page: 1555
  issue: 12
  year: 2023
  ident: 3985_CR37
  publication-title: HPB (Oxford).
  doi: 10.1016/j.hpb.2023.08.012
– volume: 380
  start-page: 1450
  issue: 15
  year: 2019
  ident: 3985_CR2
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra1713263
– volume: 42
  start-page: 38
  issue: 1
  year: 2023
  ident: 3985_CR41
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-023-02609-0
– volume: 39
  start-page: 26
  issue: 1
  year: 2019
  ident: 3985_CR42
  publication-title: Semin. Liver Dis.
  doi: 10.1055/s-0038-1676806
– volume: 15
  start-page: 625
  issue: 1
  year: 2018
  ident: 3985_CR9
  publication-title: Clin. Pract. (Lond)
– volume: 77
  start-page: 397
  issue: 2
  year: 2022
  ident: 3985_CR25
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2022.02.032
– volume: 20
  issue: 12
  year: 2021
  ident: 3985_CR44
  publication-title: Aging Cell
  doi: 10.1111/acel.13512
– volume: 7
  start-page: 503
  issue: 3
  year: 2023
  ident: 3985_CR20
  publication-title: Ann. Gastroenterol. Surg.
  doi: 10.1002/ags3.12637
– volume: 20
  start-page: 250
  issue: 4
  year: 2023
  ident: 3985_CR23
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-023-00734-5
– volume: 145
  start-page: 17377
  issue: 31
  year: 2023
  ident: 3985_CR11
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.3c05052
– volume: 531
  start-page: 253
  issue: 7593
  year: 2016
  ident: 3985_CR28
  publication-title: Nature
  doi: 10.1038/nature16969
– volume: 2
  issue: 1
  year: 2023
  ident: 3985_CR31
  publication-title: Precis. Nutr.
SSID ssj0000529419
Score 2.4499633
Snippet Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the...
Abstract Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the...
SourceID doaj
proquest
pubmed
crossref
springer
SourceType Open Website
Aggregation Database
Index Database
Publisher
StartPage 20090
SubjectTerms 631/67
692/53
692/700
Adult
Aged
Albumin
Biomarkers
Biomarkers, Tumor - blood
C-Reactive Protein - analysis
C-Reactive Protein - metabolism
Cancer
Female
Humanities and Social Sciences
Humans
Immune response
Kaplan-Meier Estimate
Liver cancer
Liver Neoplasms - blood
Liver Neoplasms - diagnosis
Liver Neoplasms - mortality
Liver Neoplasms - pathology
Lymphocytes
Lymphocytes - metabolism
Male
Middle Aged
multidisciplinary
Neoplasm Staging
Nomogram
Nomograms
Nutrition
Nutritional status
Patients
Prognosis
Regression analysis
Retrospective Studies
ROC Curve
Science
Science (multidisciplinary)
Serum Albumin - analysis
Serum Albumin - metabolism
Survival
Survival analysis
The CALLY index
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NatwwEBYhEOiltOmf26So0FsqIluyLB2T0BAKCSVsITch64cWgjd0ncPmlHfoG_ZJMiN5Nylt6aUnG3sQkmak-cSMviHkvWp0cIIn1omgmVTaMVf7nsWee62C4iGXezs9Uydf5KeL9uJBqS_MCSv0wGXi9nutfetbjG8BuODJtG1SGhxV6qXTwePuCz7vwWGqsHo3RtZmuiXDhd5fgKfC22RNy7gwumXdL54oE_b_CWX-FiHNjuf4CXk8IUZ6UHr6lGzEYZtslRqSy2fkBhRNj84__7z9kVONvw3wdrkEJc39cow00yHS6cLdgsbha4754xfMsYNGKRJ-oyC9xCQN6lEAHlN2Oh3nFFAinZ2dUoCSWNSIFv7n52R2_HF2dMKmggrMS6FHlgBuJe4AVQURk0wuRN45OKBpU3uVXNfXPnY8xBYOYp3DFDYTwaOHYHzwTrwgm8N8iK8INSLVjRNSG-6kiqYXwrhkJNJ_AWLzFdlbza29KrQZNoe7hbZFExY0YbMmbFeRQ5z-tSRSXucPYAh2MgT7L0OoyM5KeXZahwuLcSSpkTOxIu_Wv2EFYVjEDXF-XWQAp8FeV5GXRenrnkikuwFQWZEPKyu4b_zvA3r9Pwb0hjxqsrkqVpsdsjl-v467gIDG_m029jtwZQH1
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection (ProQuest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkLKu-0BRmJG1h11o5jn6pSUVVIrRBapL1Zjh-AVCWlmx62J_4D_5Bfwozj3QrxOCVKRo7jGdufPeNvCHmlZjo4wRNrRdBMKu2Yq33HYse9VkHxkNO9nZ6pk0_y_aJZlA23ZQmrXI-JeaAOg8c98n30CEiN7HcHF98YZo1C72pJoXGb3EHqMgzpahftZo8FvViyNuWsDBd6fwnzFZ4pmzWMC6Mb1v42H2Xa_r9hzT_8pHn6Od4m9wtupIeToh-QW7F_SO5OmSRXj8g1qJseffzw8_uPHHD8tYe78xWoavCrMdJMikjLsbsljf2X7PnHJxhpB4VSpP1GQXqOoRrUowBcSow6HQcKWJHOz04pAEpMbUQnFujHZH78bn50wkpaBeal0CNLALoSd4CtgohJJhcibx0s07SpvUqu7WofWx5iA8ux1mEgm4kwr4dgfPBOPCFb_dDHZ4QakeqZE1Ib7qSKphPCuGQkkoABbvMVeb1uW3sxkWfY7PQW2k6asKAJmzVh24q8xebfSCLxdX4wXH62pR_ZTmvf-AbdnYA1eTJNk5QG3JI66XSAT-6tlWdLb1zaG9upyMvNa-hH6BxxfRyuJhlAazDiVeTppPRNTSSS3gC0rMibtRXcFP7vH9r5f112yb1ZNkTFarNHtsbLq_gcEM7Yvchm_AsBx_oB
  priority: 102
  providerName: ProQuest
Title The CRP–albumin–lymphocyte index provides enhanced prognostic value in liver cancer compared to the TNM staging system
URI https://link.springer.com/article/10.1038/s41598-025-03985-7
https://www.ncbi.nlm.nih.gov/pubmed/40537551
https://www.proquest.com/docview/3222486595
https://www.proquest.com/docview/3222639073
https://doaj.org/article/b88c5c538165400f955f68215fb4a8dc
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB71ISQuiDeBsjISN7BIYsexj9tVq2qlrqqySHuzHD-gUpWgbnpYTvwH_iG_hLGTXYQoB06JnInjeGzPZ8_4M8BbUUpnWB5ozZykXEhDTWEb6pvcSuFE7tJxb-cLcfaJz1fVag_K7V6YFLSfKC3TML2NDvuwRkMTN4OVFc2ZkhWt9-EwUrfHVj0Ts926SvRc8UKN-2NyJu949Q8blKj678KXf_lGk8k5fQgPRqxIpkPpHsGebx_DveH0yM0T-IYqJrPLi5_ff6Qg46sW7643qJ7ObnpPEhEiGbfarYlvvyRvf0yJ0XWYKYlU31GQXMfwDGKjAF7GuHTSdwTxIVkuzgmCyHicERmYn5_C8vRkOTuj41EK1HImexoQaIXcIJ5yzAcejPN5bXBqJlVhRTB1U1hf585XOAWrTQxeUx5tuXPKOmvYMzhou9a_AKJYKErDuFS54cKrhjFlguKR-Auxms3g3bZu9deBMEMnRzeTetCERk3opAldZ3Acq38nGcmuU0J381mPyteNlLayVXRxIr7Mg6qqICRildBwIx1-8mirPD32wLWOHiQuI1tiBm92j7HvRIeIaX13O8ggQsNRLoPng9J3JeGR6AbhZAbvt63gd-b__qGX_yf-Cu6XqWEKWqgjOOhvbv1rRDl9M4H9elVP4HA6nX-c4_X4ZHFxOUmNfZJWDn4BStH83w
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbKVoheEL_tQgEjwQmsJrGT2AeEaGm1pd1VVS1Sb5bjH0CqktLdCi0n3oHn4KV4EmacZCvEz62nRMnIcTwz9jee8Qwhz4pMOsOTwEruJBOFNMyktmK-SqwsXJG4WO5tPClG78W7k_xkhfzoz8JgWGU_J8aJ2jUW98i30CMgJGa_e332mWHVKPSu9iU0WrE48IsvYLLNXu2_Bf4-z7K93enOiHVVBZgVXM5ZAMwREgPQwnEfRDDOJ6UBK0Wq1BbBlFVqfZk4n4M1UhqM41IeljXnlHXWcGj2GlkVHCyZAVnd3p0cHS83ddBtJlLVHc5JuNyawQKJh9iynCVcyZyVvy2AsU7A38DtH47ZuN7t3SI3O6BK37SSdZus-PoOud6WrlzcJV9BvujO8dHPb99jhPOnGu5OFyAbjV3MPY1ZGGl3zm9Gff0xhhrgEwztg0Yp5hlHQnqKsSHUIgFcuqB4Om8ogFM6nYwpIFispUTbtNP3yPQqRvw-GdRN7TcIVTykmeFCqsSIwquKc2WCEph1DICiHZIX_djqszZbh45edi51ywkNnNCRE7ockm0c_iUlZtqOD5rzD7pTXF1JaXObo38VwG0SVJ6HQgJQCpUw0sEnN3vm6U79Z_pSWIfk6fI1KC56Y0ztm4uWBuAhTLFDst4yfdkTgVl2AMsOycteCi4b__cPPfh_X56QG6Pp-FAf7k8OHpK1LAplwVK1SQbz8wv_CODVvHrcCTUl-orV6BcyZDj1
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYhLxbOkFDASnMDaJHYS-4AQtKxaSlcVWqS9WY4fgFQlpbsVWk78B34Nf4dfwoyTbIV43HpKlIwcxzNjf_a8CHlc5tIZngZWcSeZKKVhJrM183VqZenK1MVyb4eTcu-9eDMrZmvkxxALg26Vw5wYJ2rXWjwjH6FFQEjMfjcKvVvE0e74xclnhhWk0NI6lNPoROTAL7_A9m3-fH8XeP0kz8evpzt7rK8wwKzgcsEC4I-QGoAZjvsggnE-rQzsWKTKbBlMVWfWV6nzBexMKoM-XcrDEuecss4aDs1eIpcrXmSoYtWsWh3voAFNZKoP00m5HM1hqcRwtrxgKVeyYNVvS2GsGPA3mPuHiTaufOPrZKOHrPRlJ2M3yJpvbpIrXRHL5S3yFSSN7rw7-vnte_R1_tTA3fESpKS1y4WnMR8j7SP-5tQ3H6PTAT5BJz9olGLGcSSkx-glQi0SwKV3j6eLlgJMpdPJIQUsi1WVaJeA-jaZXsR43yHrTdv4u4QqHrLccCFVakTpVc25MkEJzD8GkNEm5Okwtvqky9uho72dS91xQgMndOSErhLyCod_RYk5t-OD9vSD7lVY11LawhZoaQWYmwZVFKGUAJlCLYx08MntgXm6nwjm-lxsE_Jo9RpUGO0ypvHtWUcDQBEm24Rsdkxf9URgvh1AtQl5NkjBeeP__qGt__flIbkKyqPf7k8O7pFreZTJkmVqm6wvTs_8fcBZi_pBlGhK9AVr0C9E0jvF
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+CRP-albumin-lymphocyte+index+provides+enhanced+prognostic+value+in+liver+cancer+compared+to+the+TNM+staging+system&rft.jtitle=Scientific+reports&rft.au=Zhao%2C+Hong&rft.au=Yin%2C+Bing&rft.au=Li%2C+Xiang-Rui&rft.au=Liu%2C+Xiao-Yue&rft.date=2025-06-19&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=15&rft.issue=1&rft.spage=20090&rft_id=info:doi/10.1038%2Fs41598-025-03985-7&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon